Drug Trial Radar · NCT06439381
Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Jul 16, 2024
Primary completion
Dec 19, 2025
Study completion Dec 19, 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, continuing, Phase II expansion trial to evaluate the safety, efficacy, and immunogenicity of two doses of TQH2722 in the long-term treatment of severe chronic sinusitis with or without nasal polyps.
Conditions
- Chronic Rhinosinusitis
Interventions
300mg/600mg of TQH2722 injectionDrug
TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse events (TEAE)Time frame: Up to 32 weeks
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First People's Hospital of Foshan
Foshan, Guangdong, China
The Second People's Hospital of Shenzhen
Shenzhen, Guangdong, China
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
Hebei Medical University Third Hospital
Shijiazhuang, Hebei, China
Cangzhou Central Hospital
Cangzhou, Heibei, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of science and technology
Wuhan, Hubei, China
Renmin Hospital of Wuhan University Hubei General Hospital
Wuhan, Hubei, China
Loudi Central Hospital
Changsha, Hunan, China
Baotou Central Hospital
Baotou, Inner Mongolia, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Jilin Provincial People's Hospital
Changchun, Jilin, China
The Affiliated Hospital of Yanbian University
Yanji, Jilin, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China
The Central Hospital of Shenyang Medical College
Shenyang, Liaoning, China
Shandong Second People's Hospital
Jinan, Shandong, China
Weihai Central Hospital
Weihai, Shandong, China
Yantai Yuhuangding Hospital
Yantai, Shandong, China
Zibo Central Hospital
Zibo, Shandong, China
Renji Hospital Shanghai Jiaotong University School of Medical
Shanghai, Shanghai Municipality, China
First Hospital of Shangxi Medical University
Taiyuan, Shangxi, China
Chengdu Second People's Hospital
Chengdu, Sichuan, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Taizhou central hospital(Taizhou university hospital)
Taizhou, Zhejiang, China
Wenling First People's Hospital
Wenling, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.